Another study in hepatocellular carcinoma developed an ac4C Score model, demonstrating that high-score tumors exhibited advanced staging, higher p53 mutation rates, elevated tumor stemness, increased immune scores, and heightened regulatory T cell infiltration, suggesting the ac4C Score as a novel prognostic indicator for anti-PD1 immunotherapy response (Liu et al., 2022b). This evidence concerns the gene TP53 and hepatocellular carcinoma.